Search Result

Results for "

FGFR-IN-2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FGFR (23) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (3) Bcr-Abl (1) c-Fms (1) c-Met/HGFR (2) Cytochrome P450 (1) FLT3 (1) Isotope-Labeled Compounds (2) Necroptosis (1) PDGFR (8) PROTACs (1) VEGFR (9)
By Research Areas:	Cancer (23) Inflammation/Immunology (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: FGFR Dan family AIM2 NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19983

ASP5878	FGFR	Cancer
ASP5878 is an oral active inhibitor of FGFR 1, 2, 3, and 4, with IC₅₀ values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity. ASP5878 has potential antineoplastic activity .

HY-12965

S49076 1 Publications Verification	FGFR c-Met/HGFR	Cancer
S49076 is a novel, potent inhibitor of MET, AXL/MER, and *FGFR1/2/3* with IC₅₀ values below 20 nM.

HY-15813

FIIN-1 FGFR irreversible INhibitor-1	FGFR	Cancer
FIIN-1 is a potent, irreversible, selective *FGFR* inhibitor. FIIN-1 binds to *FGFR1/2/3/4* and Flt1/4 with K_ds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC₅₀s of FIIN-1 are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively .

HY-163705

BR-cpd7	PROTACs FGFR	Cancer
BR-cpd7 is a PROTAC degrader for fibroblast growth factor receptor *FGFR1/2* with DC₅₀ of 10 nM. BR-cpd7 arrests cell cycle, inhibits proliferations of FGFR1/2 aberrant activated tumor cells. (Pink: ligand for target protein FGFR-IN-12 (HY-160013); Black: linker; Blue: ligand for E3 ligase Thalidomide-NH-CH2-COOH (HY-131717))

HY-18708

Erdafitinib 20+ Cited Publications JNJ-42756493	FGFR Apoptosis	Cancer
Erdafitinib (JNJ-42756493) is a potent and orally available *FGFR* family inhibitor; inhibits FGFR1/2/3/4 with IC₅₀s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.

HY-101466A

E7090 succinate	FGFR	Cancer
E7090 succinate is an orally available, selective and potent inhibitor of **FGFR1, FGFR2 and FGFR3 tyrosine kinase activities, with IC₅₀** values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively .

HY-142921

*FGFR-IN-2*	FGFR	Cancer
FGFR-IN-2 (compound 1) is a potent *FGFR* inhibitor with IC₅₀s of 7.3 nM, 4.3 nM, 7.6 nM, 11 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FGFR-IN-2 has the potential for cancer research .

HY-12965A

S49076 hydrochloride	FGFR c-Met/HGFR	Cancer
S49076 hydrochloride is a novel, potent inhibitor of MET, AXL/MER, and *FGFR1/2/3* with IC₅₀ values below 20 nM.

HY-147713

FGFR3-IN-1	FGFR	Cancer
FGFR3-IN-1 (compound 1) is a fibroblast growth factor receptor (FGFR) inhibitor, with IC₅₀s of 40 nM, 5.1 nM, and 12 nM for *FGFR1*, 2, and 3, respectively. FGFR3-IN-1 can be used for the research of bladder cancer .

HY-147715

FGFR3-IN-3	FGFR	Cancer
FGFR3-IN-3 (compound 40a) is a potent and pan-FGFR inhibitor, with IC₅₀s of 2.1 nM, 3.1 nM, 4.3 nM and 74 nM for *FGFR1*, 2, 3, and 4, respectively. FGFR3-IN-3 can be used for the research of bladder cancer .

HY-18708R

Erdafitinib (Standard)	FGFR Apoptosis	Cancer
Erdafitinib (Standard) is the analytical standard of Erdafitinib. This product is intended for research and analytical applications. Erdafitinib (JNJ-42756493) is a potent and orally available *FGFR* family inhibitor; inhibits FGFR1/2/3/4 with IC₅₀s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.

HY-50904

Nintedanib Maximum Cited Publications 51 Publications Verification BIBF 1120	PDGFR VEGFR FGFR	Cancer
Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for *VEGFR1/2/3, FGFR1/2/3* and PDGFRα/β with IC₅₀s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-159503A

Segigratinib hydrochloride 3D185; HH185	FGFR c-Fms	Cancer
Segigratinib hydrochloride (3D185) is a potent inhibitor of *FGFR1/2/3* and CSF-1R; The IC₅₀ values for FGFR1, FGFR2, FGFR3 and CSF-1R are 0.5, 1.3, 3.6 and 3.8 nM, respectively. Segigratinib hydrochloride has antitumor activity .

HY-11106

Nintedanib esylate Maximum Cited Publications 51 Publications Verification BIBF 1120 esylate	PDGFR VEGFR FGFR	Cancer
Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for *VEGFR1/2/3, FGFR1/2/3* and PDGFRα/β with IC₅₀s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-50904S

Nintedanib-d3 BIBF 1120-d₃	PDGFR VEGFR FGFR	Cancer
Nintedanib-d₃ is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-131244

ALK-IN-9	Anaplastic lymphoma kinase (ALK)	Cancer
ALK-IN-9 (compound 40) is a potent ALK inhibitor. ALK-IN-9 inhibits cell proliferation with IC₅₀s of <0.2 nM, <0.2 nM, 0.2 nM for Ba/F3-EML4-ALK, KM 12 (TPM3-TRKA), KG-l cell (OP2-FGFR1), respectively .

HY-50904S2

Nintedanib-d8 BIBF 1120-d₈	Isotope-Labeled Compounds PDGFR VEGFR FGFR	Cancer
Nintedanib-d₈ is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-50904R

Nintedanib (Standard)	PDGFR VEGFR FGFR	Cancer
Nintedanib (Standard) is the analytical standard of Nintedanib. This product is intended for research and analytical applications. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for *VEGFR1/2/3, FGFR1/2/3* and PDGFRα/β with IC₅₀s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-50904S1

Nintedanib-13C,d3 BIBF 1120-¹³C,d₃	Isotope-Labeled Compounds PDGFR VEGFR FGFR	Cancer
Nintedanib- ¹³C,d₃ is the ¹³C- and deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-11106R

Nintedanib esylate (Standard)	PDGFR VEGFR FGFR	Cancer
Nintedanib esylate (Standard) is the analytical standard of Nintedanib esylate. This product is intended for research and analytical applications. Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for *VEGFR1/2/3, FGFR1/2/3* and PDGFRα/β with IC₅₀s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-100818

Futibatinib 3 Publications Verification TAS-120	FGFR	Cancer
Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible *FGFR* inhibitor, with IC₅₀s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC₅₀s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM) ^[2] .

HY-100818R

Futibatinib (Standard)	FGFR	Cancer
Futibatinib (Standard) is the analytical standard of Futibatinib. This product is intended for research and analytical applications. Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible *FGFR* inhibitor, with IC₅₀s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC₅₀s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM) ^[2] .

HY-170846

FGFRs-IN-1	FGFR VEGFR Bcr-Abl FLT3 Cytochrome P450	Inflammation/Immunology
FGFRs-IN-1 (Compound A16) is the orally active inhibitor for *FGFR, that inhibits FGFR1/2/3/4* with IC₅₀s of 2.3, 7, 11, and 163 nM, respectively. FGFRs-IN-1 also inhibits *VEGFR1/2/3, Abl, and Flt3* with IC₅₀s of 61, 176, 112, 26, and 353 nM, respectively. FGFRs-IN-1 exhibits weak inhibitory efficacy against CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and inhibits epithelial-mesenchymal transition (EMT) in TGF-β1 stimulated A549 cell. FGFRs-IN-1 exhibits anti-inflammatory activity in Bleomycin (HY-17565)-induced mouse pulmonary fibrosis model and CCl₄ (HY-Y0298)-induced mouse liver fibrosis model .

HY-161995

FGFR1/VEGFR2-IN-2	Apoptosis Necroptosis FGFR VEGFR PDGFR	Cancer
FGFR1/VEGFR2-IN-2 (compound 6l) is a *VEGFR2/FGFR1* dual inhibitor. The IC₅₀ values for *VEGFR2* and *FGFR1* are 0.025 µM and 0.026 µM respectively, and for EGFR and PDGFR-β, the IC₅₀ values are 0.106 µM and 0.077 µM. FGFR1/VEGFR2-IN-2 showes significant anti-cancer activity (GI=60.38%) on NCI-60 cell line, with an IC₅₀ of 8.51 µM in T-47D cell line and anti-migration. FGFR1/VEGFR2-IN-2 acts to arrest cells in the G1 phase and promote apoptosis and necrosis; the IC₅₀ for MCF-7 cell line exceeds 100 µM, and the IC₅₀ for MDA-MB-231 is 69.17 µM, non-toxic to normal cells .

Cat. No.	Product Name	Chemical Structure

HY-50904S2

Nintedanib-d8
Nintedanib-d₈ is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-50904S1

Nintedanib-13C,d3
Nintedanib- ¹³C,d₃ is the ¹³C- and deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-50904S

Nintedanib-d3
Nintedanib-d₃ is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.